Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Merus NV MRUS

Healthcare Biotechnology

Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's... see more

Add To Watchlist

Recent & Breaking News (NDAQ:MRUS)

Report: Exploring Fundamental Drivers Behind Gladstone Commercial, IRHYTHM TECH, Jounce Therapeutics, CoStar Group, Tecnoglass, and Merus N.V — New Horizons, Emerging Trends, and Upcoming Developments

GlobeNewswire March 16, 2018

Merus Announces Ono Pharmaceuticals Exercise of its Option for New Research and License Agreement to Generate Bispecific Antibody Targeting Autoimmune Diseases

GlobeNewswire March 14, 2018

Merus’ Intellectual Property Portfolio Expands with Two New Patents

GlobeNewswire March 13, 2018

Merus to Present at the Cowen & Co. 38th Annual Health Care Conference

GlobeNewswire March 6, 2018

Merus Announces Participation in Four Investor Conferences in February 2018

GlobeNewswire February 5, 2018

Merus Announces First Patient Dosed in a Phase 2 Clinical Trial of MCLA-128 in Two Metastatic Breast Cancer Patient Populations

GlobeNewswire January 26, 2018

Merus and Simcere Announce Strategic Collaboration on Multiple Bispecific Antibodies

GlobeNewswire January 8, 2018

Merus Provides Clinical Updates for MCLA-117 and MCLA-158 Programs

GlobeNewswire January 4, 2018

Mid-Afternoon Market Update: Dow Gains 60 Points; Net Element Shares Spike Higher

Benzinga.com January 2, 2018

Mid-Day Market Update: NASDAQ Up Over 1%; Merus Shares Plummet

Benzinga.com January 2, 2018

Merus to Present at the 36th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 2, 2018

Merus Announces the U.S. Court of Appeals for the Federal Circuit Denies Regeneron's Petition to Rehear the Panel's Decision Affirming Merus' Inequitable Conduct Claim Against Regeneron

GlobeNewswire December 27, 2017

Merus Announces Third Quarter 2017 Financial Results and Clinical Highlights

GlobeNewswire November 30, 2017

Merus to Present at the Jefferies London Healthcare Conference

GlobeNewswire November 9, 2017

Merus to Participate in the BIO Investor Forum

GlobeNewswire October 10, 2017

Merus’ Intellectual Property Portfolio Expands with Two New Patents For its Biclonics® Technology

GlobeNewswire September 20, 2017

Merus Announces Second Quarter 2017 Financial Results and Highlights Recent Progress

GlobeNewswire September 19, 2017

Merus to Participate in Two Investor Conferences in September 2017

GlobeNewswire August 30, 2017

Merus to Present at the 2017 Wedbush PacGrow Healthcare Conference

GlobeNewswire August 9, 2017

U.S. Court of Appeals for the Federal Circuit Affirms Merus’ Inequitable Conduct Claim Against Regeneron

GlobeNewswire July 28, 2017